Cantor Fitzgerald Lifts AbbVie Price Target to $290 as Stock Hovers Near 52-Week High

By TrendSpider Editor

With ABBV already pressing against the upper boundary of its 52-week range, the forward setup hinges on whether the stock can sustain momentum and clear $274.94 on a closing basis. A confirmed Buy rating with a price target above current highs offers a constructive narrative, but price action will n

Cantor Fitzgerald Lifts AbbVie Price Target to $290 as Stock Hovers Near 52-Week High

Key Drivers of the ABBV Stock Move

• Main Catalyst: Cantor Fitzgerald's Carter Gould confirmed a Buy rating on ABBV and raised the firm's price target to $290, up from the prior target of $285, representing a $5 increase in the firm's valuation outlook.
• Bull Case: The new $290 price target sits above ABBV's current price of $272.43 and above the stock's all-time 52-week high of $274.94, suggesting the analyst sees room for the stock to push into new high territory. A confirmed Buy at this level from an active coverage firm carries added weight given the stock's proximity to peak valuations.
• Bear Case: Despite the raised price target, ABBV shares are essentially flat on the session at $272.43 with a 0.00% price move, suggesting the market is not materially re-rating the stock on this news alone. Trading this close to the 52-week high of $274.94 leaves limited technical runway before the stock would need to break into uncharted ground, which historically introduces increased volatility risk.

With ABBV already pressing against the upper boundary of its 52-week range, the forward setup hinges on whether the stock can sustain momentum and clear $274.94 on a closing basis. A confirmed Buy rating with a price target above current highs offers a constructive narrative, but price action will need to confirm the breakout. Investors should watch for any upcoming catalysts, including pipeline updates or broader pharmaceutical sector developments, that could serve as the fundamental fuel needed to push the stock into new territory heading into the back half of October 2026.

ABBV Analyst Ratings and Price Targets

Cantor Fitzgerald, through analyst Carter Gould, has confirmed its Buy rating on AbbVie while lifting its price target to $290 from a prior target of $285. This is the sole analyst action on ABBV today, with no upgrades or downgrades recorded in the session. The average price target across coverage currently stands at $290, aligning precisely with Cantor Fitzgerald's updated figure. The consensus rating remains constructive, and the raised target reflects a modest but deliberate step-up in the firm's valuation framework for the stock at current levels.

ABBV Seasonality

October has historically been a transitional month for large-cap healthcare and pharmaceutical names, with analyst activity often picking up ahead of year-end portfolio positioning. A confirmed Buy rating in the second week of October could be timed to front-run potential Q3 earnings-driven catalysts later in the month.

ABBV Relative Performance

ABBV's current price of $272.43 places it within roughly 1% of its 52-week high of $274.94, a position that reflects significant outperformance relative to where it traded at its 52-week low of $191. That represents a gain of more than 40% from trough to current levels, suggesting ABBV has broadly outpaced many of its large-cap pharmaceutical peers over the trailing year. With the stock essentially flat on today's session, near-term relative performance will depend on whether broader sector sentiment and pipeline developments can support a push beyond current resistance.